- Home
- ASMB vs MCRB Comparison
ASMB vs MCRB Comparison
Compare ASMB & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- MCRB
- Stock Information
- Founded
- ASMB 2005
- MCRB 2010
- Country
- ASMB United States
- MCRB United States
- Employees
- ASMB N/A
- MCRB N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- MCRB Health Care
- Exchange
- ASMB Nasdaq
- MCRB Nasdaq
- Market Cap
- ASMB 76.9M
- MCRB 72.0M
- IPO Year
- ASMB 2010
- MCRB 2015
- Fundamental
- Price
- ASMB $15.40
- MCRB $7.00
- Analyst Decision
- ASMB Strong Buy
- MCRB Hold
- Analyst Count
- ASMB 3
- MCRB 5
- Target Price
- ASMB $33.00
- MCRB $73.67
- AVG Volume (30 Days)
- ASMB 14.3K
- MCRB 93.5K
- Earning Date
- ASMB 05-08-2025
- MCRB 05-07-2025
- Dividend Yield
- ASMB N/A
- MCRB N/A
- EPS Growth
- ASMB N/A
- MCRB N/A
- EPS
- ASMB N/A
- MCRB 8.98
- Revenue
- ASMB $32,154,000.00
- MCRB N/A
- Revenue This Year
- ASMB $33.96
- MCRB N/A
- Revenue Next Year
- ASMB N/A
- MCRB N/A
- P/E Ratio
- ASMB N/A
- MCRB $0.78
- Revenue Growth
- ASMB 148.33
- MCRB N/A
- 52 Week Low
- ASMB $7.75
- MCRB $6.53
- 52 Week High
- ASMB $19.93
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- ASMB 69.79
- MCRB 38.60
- Support Level
- ASMB $13.13
- MCRB $7.32
- Resistance Level
- ASMB $14.35
- MCRB $7.33
- Average True Range (ATR)
- ASMB 0.73
- MCRB 0.59
- MACD
- ASMB 0.10
- MCRB 0.09
- Stochastic Oscillator
- ASMB 84.79
- MCRB 26.11
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.